Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Invivo Therapeutics Holdings (DE:04I)
FRANKFURT:04I
Invivo Therapeutics Holdings (04I) Stock Price & Analysis
0 Followers
04I Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.14 - €1.98
Previous Close€0.25
Volume0.00
Average Volume (3M)16.95K
Market Cap
€859.95K
Enterprise Value-€7.07M
Total Cash (Recent Filing)$8.58M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
Beta0.17
Next Earnings
Apr 01, 2019EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,105,446
10 Day Avg. Volume0
30 Day Avg. Volume16,955
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.26
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.78
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Invivo Therapeutics Holdings News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
04I FAQ
What was Invivo Therapeutics Holdings’s price range in the past 12 months?
Invivo Therapeutics Holdings lowest stock price was €0.14 and its highest was €1.98 in the past 12 months.
What is Invivo Therapeutics Holdings’s market cap?
Currently, no data Available
When is Invivo Therapeutics Holdings’s upcoming earnings report date?
Invivo Therapeutics Holdings’s upcoming earnings report date is Apr 01, 2019 which is 1846 days ago.
How were Invivo Therapeutics Holdings’s earnings last quarter?
Invivo Therapeutics Holdings released its earnings results on Nov 08, 2018. The company reported -€290.942 earnings per share for the quarter, missing the consensus estimate of N/A by -€290.942.
Is Invivo Therapeutics Holdings overvalued?
According to Wall Street analysts Invivo Therapeutics Holdings’s price is currently Overvalued.
Does Invivo Therapeutics Holdings pay dividends?
Invivo Therapeutics Holdings does not currently pay dividends.
What is Invivo Therapeutics Holdings’s EPS estimate?
Invivo Therapeutics Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invivo Therapeutics Holdings have?
Currently, no data Available
What happened to Invivo Therapeutics Holdings’s price movement after its last earnings report?
Invivo Therapeutics Holdings reported an EPS of -€290.942 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Invivo Therapeutics Holdings?
Currently, no hedge funds are holding shares in DE:04I
---
Invivo Therapeutics Holdings Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.92%
12-Months-Change
Fundamentals
Return on Equity
-98.11%
Trailing 12-Months
Asset Growth
-28.24%
Trailing 12-Months
Company Description
Invivo Therapeutics Holdings
Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company was founded by Joseph P. Vacanti, Frank M. Reynolds, and Robert Langer in January 2005 and is headquartered in Cambridge, MA.
---
Technical Analysis
Invivo Therapeutics Holdings
―
Protalix
―
Sarepta Therapeutics
―
Sangamo Biosciences
―
Voyager Therapeutics
―
---